JP7657792B2 - メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 - Google Patents

メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 Download PDF

Info

Publication number
JP7657792B2
JP7657792B2 JP2022525903A JP2022525903A JP7657792B2 JP 7657792 B2 JP7657792 B2 JP 7657792B2 JP 2022525903 A JP2022525903 A JP 2022525903A JP 2022525903 A JP2022525903 A JP 2022525903A JP 7657792 B2 JP7657792 B2 JP 7657792B2
Authority
JP
Japan
Prior art keywords
ethoxy
substituted
bipyridine
trifluoromethyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553832A (ja
JP2022553832A5 (enExample
Inventor
ハン，シャンドン
ヒ キム，ソン
ヂウ，ユンフェイ
Original Assignee
クリネティックス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリネティックス ファーマシューティカルズ，インク． filed Critical クリネティックス ファーマシューティカルズ，インク．
Publication of JP2022553832A publication Critical patent/JP2022553832A/ja
Publication of JP2022553832A5 publication Critical patent/JP2022553832A5/ja
Priority to JP2025050448A priority Critical patent/JP2025109202A/ja
Application granted granted Critical
Publication of JP7657792B2 publication Critical patent/JP7657792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022525903A 2019-11-07 2020-10-30 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 Active JP7657792B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050448A JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932306P 2019-11-07 2019-11-07
US62/932,306 2019-11-07
PCT/US2020/058202 WO2021091788A1 (en) 2019-11-07 2020-10-30 Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050448A Division JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Publications (3)

Publication Number Publication Date
JP2022553832A JP2022553832A (ja) 2022-12-26
JP2022553832A5 JP2022553832A5 (enExample) 2023-11-07
JP7657792B2 true JP7657792B2 (ja) 2025-04-07

Family

ID=75849034

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525903A Active JP7657792B2 (ja) 2019-11-07 2020-10-30 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP2025050448A Pending JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050448A Pending JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Country Status (4)

Country Link
US (1) US12479825B2 (enExample)
EP (1) EP4054583A4 (enExample)
JP (2) JP7657792B2 (enExample)
WO (1) WO2021091788A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7359783B2 (ja) 2018-06-05 2023-10-11 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7657792B2 (ja) 2019-11-07 2025-04-07 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
PT4077307T (pt) * 2019-12-18 2025-06-03 Crinetics Pharmaceuticals Inc Antagonistas do recetor de subtipo 2 da melanocortina (mc2r) à base de piperidina gem-dissubstituída e suas utilizações
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ，インク． スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
IL305952A (en) 2021-03-19 2023-11-01 Crinetics Pharmaceuticals Inc Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment
US20230405157A1 (en) * 2022-05-10 2023-12-21 Radionetics Oncology, Inc. Melanocortin type 2 receptor (mc2r) targeted therapeutics and uses thereof
GB202302618D0 (en) 2023-02-23 2023-04-12 Omass Therapeutics Ltd MC2R modulator compounds
WO2024175928A1 (en) 2023-02-23 2024-08-29 Omass Therapeutics Limited Mc2r modulator compounds
GB202302629D0 (en) 2023-02-23 2023-04-12 Omass Therapeutics Ltd MC2R modulator compounds
EP4714953A1 (en) * 2023-05-16 2026-03-25 Scohia Pharma, Inc. Melanocortin 2-type receptor antagonist
WO2026047334A1 (en) 2024-08-28 2026-03-05 Omass Therapeutics Limited Mc2r modulator compounds
WO2026047337A1 (en) 2024-08-28 2026-03-05 Omass Therapeutics Limited Mc2r modulator compounds
GB202412595D0 (en) 2024-08-28 2024-10-09 Omass Therapeutics Ltd Mc2r modulator compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002538A1 (fr) 2001-06-29 2003-01-09 Kowa Co., Ltd. Derive de bis(2-aryl-5-pyridyle)
JP2012500785A (ja) 2008-08-22 2012-01-12 ノバルティス アーゲー Ｃｄｋ阻害剤としてのピロロピリミジン化合物
JP2012501317A (ja) 2008-09-02 2012-01-19 ノイロサーチ アクティーゼルスカブ トリアゾール誘導体、及びそのニコチン性アセチルコリン受容体モジュレーターとしての使用
JP2012532137A (ja) 2009-06-29 2012-12-13 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
WO2019014460A1 (en) 2017-07-12 2019-01-17 The Brigham And Women's Hospital, Inc. MOLECULES ENHANCING EAAT2
WO2019079373A1 (en) 2017-10-17 2019-04-25 Merck Patent Gmbh PYRIMIDINE TBK / IKKε INHIBITORY COMPOUNDS AND USES THEREOF
JP7359783B2 (ja) 2018-06-05 2023-10-11 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284956A (en) 1988-09-06 1994-02-08 Hoffmann-La Roche Inc. Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines
JP2881750B2 (ja) * 1988-09-06 1999-04-12 エフ・ホフマン‐ラ ロシユ アーゲー ２‐（２‐フルオロフエニル）‐ピリジン
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
EP1465867A1 (en) 2001-10-09 2004-10-13 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
AR037429A1 (es) 2001-11-26 2004-11-10 Schering Corp Derivados de piperidina antagonistas de la mch, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos derivados, solos o en combinacion, para la fabricacion de un medicamento para tratamiento de la obesidad y de trastornos del snc
AU2003216274A1 (en) 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
JP2005534632A (ja) 2002-05-10 2005-11-17 ニューロクライン バイオサイエンセズ， インコーポレイテッド メラノコルチンレセプターリガンドとしての置換ピペラジン
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
EP1460073A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
UA85194C2 (ru) 2003-08-11 2009-01-12 Ф.Хоффманн-Ля Рош Аг Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1
ATE374610T1 (de) 2003-09-09 2007-10-15 Hoffmann La Roche 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
AR053712A1 (es) 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
US7652024B2 (en) 2005-10-18 2010-01-26 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2303597C1 (ru) 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
WO2010026124A1 (en) 2008-09-02 2010-03-11 Novartis Ag Picolinamide derivatives as kinase inhibitors
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9281726B2 (en) 2011-05-31 2016-03-08 Linak A/S Actuator
FR3017867A1 (fr) 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
EP3199156A1 (de) 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
EP3480198B1 (en) 2016-06-30 2021-05-05 Riken Novel compound or pharmaceutically acceptable salt thereof
JP7657792B2 (ja) 2019-11-07 2025-04-07 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
PT4077307T (pt) 2019-12-18 2025-06-03 Crinetics Pharmaceuticals Inc Antagonistas do recetor de subtipo 2 da melanocortina (mc2r) à base de piperidina gem-dissubstituída e suas utilizações
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ，インク． スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
US11565011B2 (en) 2020-09-18 2023-01-31 Ncr Corporation Sterilizing media cassette
US20230405157A1 (en) 2022-05-10 2023-12-21 Radionetics Oncology, Inc. Melanocortin type 2 receptor (mc2r) targeted therapeutics and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002538A1 (fr) 2001-06-29 2003-01-09 Kowa Co., Ltd. Derive de bis(2-aryl-5-pyridyle)
JP2012500785A (ja) 2008-08-22 2012-01-12 ノバルティス アーゲー Ｃｄｋ阻害剤としてのピロロピリミジン化合物
JP2012501317A (ja) 2008-09-02 2012-01-19 ノイロサーチ アクティーゼルスカブ トリアゾール誘導体、及びそのニコチン性アセチルコリン受容体モジュレーターとしての使用
JP2012532137A (ja) 2009-06-29 2012-12-13 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
WO2019014460A1 (en) 2017-07-12 2019-01-17 The Brigham And Women's Hospital, Inc. MOLECULES ENHANCING EAAT2
WO2019079373A1 (en) 2017-10-17 2019-04-25 Merck Patent Gmbh PYRIMIDINE TBK / IKKε INHIBITORY COMPOUNDS AND USES THEREOF
JP7359783B2 (ja) 2018-06-05 2023-10-11 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP2024009837A (ja) 2018-06-05 2024-01-23 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Adrian John Clark et al.，ACTH Antagonists，Frontiers in Endocrinology，2016年08月05日，Vol. 7, Article 101，pp. 1-9，DOI: 10.3389/fendo.2016.00101

Also Published As

Publication number Publication date
JP2025109202A (ja) 2025-07-24
EP4054583A1 (en) 2022-09-14
US20230015914A1 (en) 2023-01-19
EP4054583A4 (en) 2023-10-25
US12479825B2 (en) 2025-11-25
JP2022553832A (ja) 2022-12-26
WO2021091788A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
JP2025109202A (ja) メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7651574B2 (ja) スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
US12479828B2 (en) Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CN115335369B (zh) Gem-二取代哌啶黑皮质素亚型-2受体(mc2r)拮抗剂及其用途
US9855269B2 (en) Aminoquinazoline and pyridopyrimidine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220720

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250326

R150 Certificate of patent or registration of utility model

Ref document number: 7657792

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150